BR112017000160A2 - derivados de azetidina substituidos como ligantes de taar - Google Patents

derivados de azetidina substituidos como ligantes de taar

Info

Publication number
BR112017000160A2
BR112017000160A2 BR112017000160A BR112017000160A BR112017000160A2 BR 112017000160 A2 BR112017000160 A2 BR 112017000160A2 BR 112017000160 A BR112017000160 A BR 112017000160A BR 112017000160 A BR112017000160 A BR 112017000160A BR 112017000160 A2 BR112017000160 A2 BR 112017000160A2
Authority
BR
Brazil
Prior art keywords
disorders
disease
formula
taar
binders
Prior art date
Application number
BR112017000160A
Other languages
English (en)
Inventor
RAUBER Etienne
Cecere Giuseppe
Galley Guido
Pflieger Philippe
Norcross Roger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017000160A2 publication Critical patent/BR112017000160A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

a presente invenção se refere a um composto de fórmula i os compostos de fórmulas i têm uma boa afinidade por receptores associados a aminas traço (taars), especialmente por taar1, e podem ser usados para o tratamento de depressão, transtornos de ansiedade, transtorno bipolar, transtorno de hiperatividade com déficit de atenção (tdah), transtornos relacionados ao estresse, transtornos psicóticos, esquizofrenia, doenças neurológicas, mal de parkinson, doenças neurodegenerativas, mal de alzheimer, epilepsia, enxaqueca, hipertensão, abuso de substâncias, distúrbios metabólicos, distúrbios alimentares, diabetes, complicações diabéticas, obesidade, dislipidemia, distúrbios do consumo e assimilação de energia, distúrbios e mau funcionamento de homeostase da temperatura corporal, distúrbios do sono e ritmo circadiano e distúrbios cardiovasculares.
BR112017000160A 2014-08-27 2015-08-24 derivados de azetidina substituidos como ligantes de taar BR112017000160A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14182445 2014-08-27
PCT/EP2015/069315 WO2016030310A1 (en) 2014-08-27 2015-08-24 Substituted azetidine derivatives as taar ligands

Publications (1)

Publication Number Publication Date
BR112017000160A2 true BR112017000160A2 (pt) 2017-10-31

Family

ID=51398565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000160A BR112017000160A2 (pt) 2014-08-27 2015-08-24 derivados de azetidina substituidos como ligantes de taar

Country Status (10)

Country Link
US (1) US10023559B2 (pt)
EP (1) EP3186224B1 (pt)
JP (1) JP6539724B2 (pt)
KR (1) KR101894681B1 (pt)
CN (1) CN107001259B (pt)
BR (1) BR112017000160A2 (pt)
CA (1) CA2954098A1 (pt)
MX (1) MX2016016488A (pt)
RU (1) RU2017107521A (pt)
WO (1) WO2016030310A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3430010T1 (sl) 2016-03-17 2020-10-30 F. Hoffmann-La Roche Ag Derivat 5-etil-4-metil-pirazol-3-karboksamida z aktivnostjo agonista TAAR
ES2962865T3 (es) 2016-11-18 2024-03-21 Integrative Res Laboratories Sweden Ab Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical
CA3048376A1 (en) 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
CN110437205B (zh) 2018-08-24 2022-07-08 广东东阳光药业有限公司 吡啶烯基哌啶衍生物及其用途
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2085427B (en) * 1980-10-08 1984-12-05 Robins Co Inc A H 3-phenoxyazetidines
US5130309A (en) * 1991-04-12 1992-07-14 A. H. Robins Company, Incorporated Aryloxy and aryloxyalklazetidines as antiarrhythmic and anticonvulsant agents
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
GB0007884D0 (en) * 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
DE102004061748A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Azetidin-substituierte Pyrazoline
BRPI0807813A2 (pt) 2007-02-15 2014-08-05 Hoffmann La Roche 2-amino-oxazolinas como ligantes de taar1
EP2152671A1 (en) * 2007-05-22 2010-02-17 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
CA2694362A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
WO2010059390A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Modulators of serotonin receptor
AR074231A1 (es) * 2008-11-27 2010-12-29 Boehringer Ingelheim Int Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders

Also Published As

Publication number Publication date
CN107001259A (zh) 2017-08-01
MX2016016488A (es) 2017-03-30
US20170144994A1 (en) 2017-05-25
US10023559B2 (en) 2018-07-17
EP3186224B1 (en) 2021-04-21
WO2016030310A1 (en) 2016-03-03
EP3186224A1 (en) 2017-07-05
RU2017107521A (ru) 2018-10-01
KR20170031763A (ko) 2017-03-21
KR101894681B1 (ko) 2018-09-04
CN107001259B (zh) 2019-12-06
JP2017526661A (ja) 2017-09-14
RU2017107521A3 (pt) 2019-01-22
CA2954098A1 (en) 2016-03-03
JP6539724B2 (ja) 2019-07-03

Similar Documents

Publication Publication Date Title
BR112017000160A2 (pt) derivados de azetidina substituidos como ligantes de taar
ECSP13013072A (es) Derivados de pirazol
BR112012011105A2 (pt) derivados de oxazolina para tratamento de doenças do snc
BR112013024312A2 (pt) derivados de amina heterocíclica
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA200970956A1 (ru) Селективные модуляторы рецепторов андрогена для лечения диабета
MX2009003887A (es) Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina.
MY176030A (en) Substituted benzamide derivatives
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
EA201070903A1 (ru) Замещенные спироциклические производные пиперидина как лиганды гистамин-3(h) рецептора
BR112014015832A2 (pt) derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
BR112017005236A2 (pt) composto, e, composição farmacêutica.
BR112015001771A2 (pt) derivados de carboxamida de triazol
EA201590454A1 (ru) Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона
MX2009005920A (es) Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
CL2008003053A1 (es) Compuestos derivados de (4-(piperazin-1-il)fenil)-amida del acido isoxazol-4-carboxilico; composicion farmaceutica, util para tratar tejido nervioso, depresion, ansiedad, adiccion a drogas, falla cardiaca, desordenes del sueno, obesidad, desordenes metabolicos, entre otras, a travez de la modulacion del receptor npy y2.
AR100210A1 (es) Derivados de piridina con afinidad a taar
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
AR063811A1 (es) 4-imidazoles sustituidos
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
AR101339A1 (es) Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo
AR067675A1 (es) 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc.
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
BR112016028714A2 (pt) derivados de 2-oxa-5-azabiciclo[2.2.1] heptan-3-ila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.